CAPR CAPRICOR THERAPEUTICS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: development and manufacturing of cell-based therapies and exosome technologies, focus on Deramiocel for commercial and clinical use
• • New emphasis on potential vaccine candidates using exosome technologies with unique manufacturing and regulatory challenges highlighted
• • Strategic focus on scaling manufacturing capacity including addition of 22,000 sq ft expansion to San Diego GMP facility ahead of potential commercial launch
• • Quantitative manufacturing milestone: completed San Diego facility with FDA pre-license inspection, received acceptable responses to Form 483 observations, lease at Cedars-Sinai expiring July 2026
• • Noteworthy risks this year: detailed impact of May 2025 U.S. MFN drug pricing initiatives and CMS GENEROUS, GLOBE, and GUARD models on future product revenues and federal reimbursement

Risk Factors

• • Regulatory risk: FDA Complete Response Letter in July 2025 for Deramiocel BLA, requiring additional Phase 3 HOPE-3 trial data, new PDUFA date August 22, 2026
• • Geopolitical/macro risk: Exposure to U.S. public health policy through NIH/NIAID collaboration on StealthX™ vaccine under Project NextGen initiative
• • Operational risk: Dependence on qualified donated human hearts as source material for CDCs in Deramiocel manufacturing scale-up
• • Competitive risk: Potential market disruption from alternative DMD therapies, including gene editing and exon skipping technologies by competitors like Sarepta Therapeutics
• • Financial risk: Reliance on equity financings with $318.1M cash (2025 year end) but net loss increased to $105.0M in 2025, risking dilution or funding gaps for further development

Management Discussion & Analysis

• • No specific revenue figures or YoY changes disclosed in provided text
• • No profitability, margin, or segment performance metrics mentioned
• • No cash flow, buybacks, dividends, or capital expenditure details provided
• • Forward-looking statements referenced but without specific management outlook or guidance

What are the latest CAPR SEC filings in 2026?

CAPRICOR THERAPEUTICS, INC. (CAPR) has filed a 10-K annual report on March 17, 2026, a 10-Q quarterly report on May 13, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CAPR file its most recent 10-K annual report?

CAPRICOR THERAPEUTICS, INC. (CAPR) filed its most recent 10-K annual report on March 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CAPR 10-Q quarterly reports?

CAPRICOR THERAPEUTICS, INC. (CAPR)'s most recent 10-Q quarterly report was filed on May 13, 2026. SignalX displays every CAPR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CAPR filed recently?

CAPRICOR THERAPEUTICS, INC. (CAPR)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CAPR insider trading activity (Form 4)?

SignalX aggregates every CAPR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CAPR file with the SEC?

CAPRICOR THERAPEUTICS, INC. (CAPR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CAPR filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for CAPRICOR THERAPEUTICS, INC. (CAPR).

What is CAPR's SEC CIK number?

CAPRICOR THERAPEUTICS, INC. (CAPR)'s SEC CIK (Central Index Key) number is 1133869. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1133869 to look up all CAPR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CAPR return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from CAPRICOR THERAPEUTICS, INC. (CAPR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.